SMS Pharmaceuticals Limited (NSE:SMSPHARMA)
India · Delayed Price · Currency is INR 523.00
+9.80 (1.91%)
Nov 11, 2026, 1:30 PM IST
SMS Pharmaceuticals Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 9,714 | 8,869 | 7,827 | 7,093 | 5,221 | 5,199 |
Other Revenue | 28.23 | 17.66 | - | - | - | - |
| 9,743 | 8,886 | 7,827 | 7,093 | 5,221 | 5,199 | |
Revenue Growth | 13.28% | 13.53% | 10.36% | 35.86% | 0.42% | -7.69% |
Cost of Revenue | 6,288 | 5,847 | 5,187 | 4,983 | 3,900 | 3,309 |
Gross Profit | 3,455 | 3,039 | 2,640 | 2,109 | 1,321 | 1,890 |
Selling, General & Admin | 1,052 | 918.49 | 828.53 | 658.08 | 547.63 | 515.16 |
Other Operating Expenses | 446.81 | 383.74 | 419.23 | 281.41 | 224.85 | 222.38 |
Operating Expenses | 1,905 | 1,701 | 1,591 | 1,255 | 1,094 | 1,059 |
Operating Income | 1,550 | 1,338 | 1,049 | 854.71 | 226.98 | 830.73 |
Interest Expense | -217.74 | -221.15 | -174.35 | -226.18 | -209.94 | -181.57 |
Interest & Investment Income | 6.19 | 6.19 | 6.87 | 7.58 | 7.75 | 5.6 |
Earnings From Equity Investments | 130.24 | 139.91 | 17.37 | 6.26 | -109.43 | -56.61 |
Currency Exchange Gain (Loss) | 56 | 56 | 50.78 | 28.98 | 39.05 | 25.8 |
Other Non Operating Income (Expenses) | -12.16 | -12.16 | -9.18 | -4.39 | -9.8 | 4.47 |
EBT Excluding Unusual Items | 1,513 | 1,306 | 940.54 | 666.96 | -55.4 | 628.42 |
Gain (Loss) on Sale of Assets | - | - | 0.21 | 0.37 | -0.54 | -0.04 |
Pretax Income | 1,513 | 1,306 | 940.74 | 667.33 | -55.94 | 628.38 |
Income Tax Expense | 343.26 | 286.4 | 249.39 | 169.07 | 14.65 | 6.18 |
Earnings From Continuing Operations | 1,169 | 1,020 | 691.35 | 498.26 | -70.59 | 622.2 |
Minority Interest in Earnings | - | - | 0.01 | - | - | - |
Net Income | 1,169 | 1,020 | 691.36 | 498.26 | -70.59 | 622.2 |
Net Income to Common | 1,169 | 1,020 | 691.36 | 498.26 | -70.59 | 622.2 |
Net Income Growth | 38.63% | 47.52% | 38.75% | - | - | -0.49% |
Shares Outstanding (Basic) | 94 | 91 | 85 | 85 | 85 | 85 |
Shares Outstanding (Diluted) | 94 | 91 | 85 | 85 | 85 | 85 |
Shares Change | 2.93% | 7.94% | 0.07% | - | - | - |
EPS (Basic) | 12.49 | 11.15 | 8.16 | 5.89 | -0.83 | 7.35 |
EPS (Diluted) | 12.49 | 11.15 | 8.16 | 5.89 | -0.83 | 7.35 |
EPS Growth | 34.64% | 36.64% | 38.64% | - | - | -0.49% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | -641.15 | -713.35 | -416.71 | -20.35 | -74.71 | 178.12 |
Free Cash Flow Per Share | -6.85 | -7.80 | -4.92 | -0.24 | -0.88 | 2.10 |
Dividend Per Share | - | 0.400 | 0.400 | 0.400 | 0.300 | 0.300 |
Dividend Growth | - | 0% | 0% | 33.33% | 0% | 0% |
Gross Margin | 35.46% | 34.20% | 33.73% | 29.74% | 25.30% | 36.35% |
Operating Margin | 15.91% | 15.05% | 13.40% | 12.05% | 4.35% | 15.98% |
Profit Margin | 12.00% | 11.48% | 8.83% | 7.03% | -1.35% | 11.97% |
Free Cash Flow Margin | -6.58% | -8.03% | -5.32% | -0.29% | -1.43% | 3.43% |
EBITDA | 1,954 | 1,735 | 1,387 | 1,163 | 541.39 | 1,142 |
EBITDA Margin | 20.06% | 19.53% | 17.72% | 16.40% | 10.37% | 21.97% |
D&A For EBITDA | 404.19 | 397.59 | 338.06 | 308.68 | 314.41 | 311.36 |
EBIT | 1,550 | 1,338 | 1,049 | 854.71 | 226.98 | 830.73 |
EBIT Margin | 15.91% | 15.05% | 13.40% | 12.05% | 4.35% | 15.98% |
Effective Tax Rate | 22.69% | 21.92% | 26.51% | 25.34% | - | 0.98% |
Revenue as Reported | 9,809 | 8,952 | 7,890 | 7,137 | 5,270 | 5,251 |
Advertising Expenses | - | 27.01 | 23.52 | 15.86 | 8.59 | 4 |